Case Analyses in Renal Cell Carcinoma

Key opinion leaders review clinical cases in renal cell carcinoma, focusing on recent advances, treatment options, and clinical trials impacting treatment.

EP. 1: Case 1: Metastatic Renal Cell Carcinoma, Intermediate Risk

October 29th 2021

Tom Hutson, DO, PharmD, reviews the case of a 59-year-old woman with metastatic renal cell carcinoma, with intermediate risk and the role of risk assessment in patient management.

EP. 2: Case 1: Systemic Therapy Options in RCC

November 8th 2021

The expert panel discusses systemic therapy options recommended in NCCN Guidelines for patient with intermediate- and poor-risk mRCC.

EP. 3: Case 1: Intermediate- and Poor Risk First-Line mRCC Treatments

November 8th 2021

Renal cell carcinoma experts discuss key efficacy data for first-line immunotherapy combinations in intermediate- and poor-risk patients with mRCC.

EP. 4: Case 1: CLEAR Trial in mRCC

November 8th 2021

Tom Hutson, DO, PharmD, reviews data from phase 3 CLEAR trial that evaluates efficacy and safety of frontline lenvatinib and pembrolizumab or everolimus or sunitinib.

EP. 5: Case 1: Practical Considerations in mRCC

November 8th 2021

The expert panel discusses practical considerations when choosing first-line treatment in mRCC in light of CLEAR trial data.

EP. 6: Case 1: CheckMate 9ER mRCC Trial

November 8th 2021

Tom Hutson, DO, PharmD, discusses efficacy and data from CheckMate 9ER, a phase 3 study, and considerations in selecting this regimen.

EP. 7: Case 1: Patient Management in RCC

November 8th 2021

Renal cell carcinoma panel discusses factors impacting first-line treatment selection and patient monitoring and adverse-event management in patients with intermediate- and poor-risk mRCC.

EP. 8: Case 2: Metastatic RCC, Favorable Risk

November 10th 2021

Eric Jonasch, MD, discusses a 62-year-old man with favorable-risk metastatic RCC and goals and treatment options for such a patient.

EP. 9: Case 2: Favorable-Risk First-Line Treatments in mRCC

November 10th 2021

The expert panel and Dr Eric Jonasch discuss data on first-line immunochemotherapy combinations for favorable-risk mRCC.

EP. 10: Case 2: Second-Line Treatments in Favorable-Risk mRCC

November 10th 2021

Eric Jonasch, MD, and the panel discuss NCCN Guidelines’ preferred second-line treatment options in mRCC.